Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space, especially with key drugs like Ozempic, Wegovy and Saxenda.

Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker Dicerna

Dicerna Pharmaceuticals

Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.3 billion, shares in cash of $38.25 each.  Both the Board of Directors of Novo Nordisk and Dicerna Pharmaceuticals unanimously approved this transaction.

Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%

Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021. "The acquisition of Dicerna accelerates Novo Nordisk's research within RNAi and expands the usage of the RNAi technology," said Marcus Schindler, the CSO of Novo Nordisk.

Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA)  announced it entered into a definitive agreement with Novo Nordisk A/S (NYSE: NVO) under which Novo Nordisk will acquire Dicerna. This is why.

Why Novo Nordisk (NVO) Is Buying Dicerna Pharmaceuticals (DRNA) For $3.3 Billion

(Reuters) -Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.

Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion

Novo Nordisk NVO, +0.37% NOVO.B, +0.69% said it's buying Dicerna Pharmaceuticals DRNA, -0.09% for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28.

Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals

Eli Lilly

Pfizer

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

3 Big Pharma Outperformers to Watch Out For in the Near Term

The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label extension for Novo Nordisk A/S's (NYSE: NVO) Ozempic's new dose of 2.0 mg.  Ozempic (semaglutide) is currently approved in the EU in 0.5 mg and 1.0 mg doses for type 2 diabetes in adults.

EMA Backs Approval Of Novo Nordisk's Ozempic 2mg Dose For Diabetes

Corcept Therapeutics

Regeneron Pharmaceuticals

Cassava Sciences Inc

Check out these biotech stocks that could prove to be valuable additions to your portfolio.

4 Top Biotech Stocks To Watch This Week

Bagsværd, Denmark, 8 November 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021

Bagsværd , Denmark, 5 November 202 1 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 4,109 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S' 2021 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 732.48 per share and has been calculated as the three-day volume weighted average market price from 3 November 2021 to 5 November 2021 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Novo Nordisk A/S purchases B shares worth DKK 4,109 million from Novo Holdings A/S under the 2021 share repurchase programme

Bagsværd, Denmark, 4 November 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons on 3 November 2021

Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2021 Results - Earnings Call Transcript

Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.

Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates

Novo Nordisk A/S (NYSE: NVO) Q3 sales increased 15% Y/Y (15% at CER) to DKK 35.62 billion. Diabetes and Obesity care sales drove global sales as GLP-1 sales increased by 31% at CER, Obesity care sales by 82%, and insulin sales by 4%, reflecting the uptake of Ozempic & Rybelsus and market expansion and the launch of Wegovy in the U.S.

Novo Nordisk Q3 Earnings Buoyed By Higher Diabetes And Obesity Care Sales

Drug developer Novo Nordisk on Wednesday reported third-quarter earnings lifted by strong demand for its new obesity drug.

Novo Nordisk Q3 earnings lifted by demand for new obesity drug

Financial report for the period 1 January 2021 to 30 September 2021

Novo Nordisk's net profit increased by 12% in the first nine months of 2021

Novo Nordisk A/S (NYSE: NVO) raised its forecast for sales and operating profit for FY21 after strong sales in Q3. The company expects sales and operating growth of 12-15%, up from the previous expectations of 10-13% and 9-12%, respectively.

Novo Nordisk Boosts FY21 Outlook After Solid Q3 Sales

Bagsværd, Denmark, 29 October 202 1 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.

Novo Nordisk raises sales and operating profit outlook for 2021

ARK Genomic Revolution Multi-Sector ETF

Johnson & Johnson

Investing gets simple if you have to put all of your eggs in one basket.

If I Could Only Own 1 Healthcare Stock, This Is What It Would Be

BAGHDAD--(BUSINESS WIRE)-- #BPTW4Iraq--Novo Nordisk Iraq, an affiliate of the global healthcare company with more than 90 years of innovation and leadership in diabetes care, has been officially recognized as one of the best places to work in Iraq for 2021. The company received outstanding scores across several aspects of their workplace such as leadership, organizational culture and corporate responsibility resulting in its recognition among the employers of choice in Iraq. Moreover, 94% of employees are r

Novo Nordisk Awarded the Best Place to Work Certification in Iraq For 2021

BANGKOK--(BUSINESS WIRE)-- #BPTW4Thailand--Novo Nordisk Thailand, an affiliate of the global healthcare company with more than 95 years of innovation and leadership in diabetes care, has been recognized as one of the best companies to work in Thailand both in 2020 and 2021. The company offers an award-winning culture, advancement opportunities, career training and development, high-level mentoring, mental and physical wellness initiatives, environmental and social initiatives, and competitive benefits resulting

Novo Nordisk Thailand Achieves the Best Place To Work Certification for the Second Consecutive Year

BioNTech SE

GlaxoSmithKline

Kadmon Hlds

Sanofi

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

Novo Nordisk A/S (NYSE: NVO) has agreed to pay $100 million to settle a 2017 investor suit that alleged the Company failed to disclose that it was under the same pricing pressures as its competitors. Related Content:   House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On' Unacceptably High' Insulin Prices

News for Novo Nordisk Stock (NVO)